Does addition of lapatinib to capecitabine improve outcome in women with refractory breast cancer? Commentary

Nature Clinical Practice Oncology

Volumn 4, Issue 7, 2007, Pages 398-399

  Montemurro, Filippo ^a   Aglietta, Massimo ^a,b  

^a CANDIOLO CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SOMATOMEDIN C; TAXANE DERIVATIVE; TRASTUZUMAB;

ADD ON THERAPY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG ERUPTION; DRUG POTENTIATION; DRUG WITHDRAWAL; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEART DISEASE; HUMAN; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN TARGETING; SHORT SURVEY; SIGNAL TRANSDUCTION; TUMOR GROWTH; VOMITING; WOMEN'S HEALTH;

EID: 34447262348     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0849     Document Type: Short Survey

References (5)

1. Slamon DJ et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792
2. Valabrega G et al. (2007) Trastuzumab: Mechanism of action, resistance and future perspectives in HER2 overexpressing breast cancer. Ann Oncol [doi: 10.1093/annonc/mdl475]
3. Montemurro F et al. (2006) Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy. Oncologist 11: 318-324
4. Gomez HL et al. (2006) Updated biomarker results from a phase II randomized study of lapatinib as first-line treatment for patients with ErbB2-amplified advanced or metastatic breast cancer [abstract #1090]. Breast Cancer Res Treat 100 (Suppl): S68
5. Xia W et al. (2007) Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers. Cancer Res 67: 1170-1175